CCIT for Deep Cold Storage and Cryogenic Packaging
Maintaining container closure integrity (CCI) is a critical requirement for any sterile injectable product. But when pharmaceutical products are stored at ultra-low temperatures, even the most robust packaging systems face extreme challenges. At these temperatures, materials contract and seals may loosen. Transient leaks, which don’t exist at ambient temperature, may form – putting product sterility and patient safety at risk.
For pharmaceutical manufacturers working with temperature-sensitive biologics, it is a critical challenge to ensure container closure integrity (CCI) in extreme cold conditions. This is where headspace gas ingress analysis is the only CCI testing method that is able to detect these temporary defects.
Read on to learn about a science-based, statistically validated approach to CCI testing for a pharmaceutical vial product stored at -80°C. By combining Residual Seal Force (RSF) data with non-destructive headspace gas analysis, the study offers a clear path to robust, data-driven packaging and process decisions for cold-chain products.
Why Cold Chain & Cryogenic Packaging Have at Higher CCI Failure Risk
Primary packaging that performs well at room temperature may not do so at deep cold or cryogenic storage conditions. But many advanced therapies—particularly in gene and cell therapy—require storage at -80°C or even colder. The packaging and sealing methods used for these therapies need to account for this unique stress environment. Otherwise, the risk of CCI failure—and product loss—rises significantly.
At temperatures of around -55°C and below, materials start to behave differently. Stoppers and glass vials start contracting at different rates due to differences in thermal expansion coefficients. This can create microscopic pathways that compromise CCI without leaving visible signs of damage.
In addition, these defects will seal again when returned to ambient temperature, making them undetectable with conventional testing methods. As a result, critical leak events may go unnoticed, even during validation.
Without an effective method for temporary leak detection, pharmaceutical companies risk compromised product quality, regulatory non-compliance, and costly recalls. A proactive approach is therefore needed: one that is based on robust data generation, and deep process and packaging insights to ensure the vial seal will hold across the entire cold chain.
Detecting Transient Leaks with Non-Destructive Headspace Analysis
Transient leaks are among the most elusive CCI failures. Non-destructive headspace analysis offers a unique method to detect these temporary breaches of integrity by measuring the gases inside the sealed container after exposure to a cold storage environment.
For example, when a container is stored in a dry ice environment, a defect results in carbon dioxide leaking in. When returning to ambient temperature, the container will reseal due to the gain of elasticity of the rubber stopper. This resealing process traps the carbon dioxide gas inside and will result in measurable levels of CO2 in the headspace of the container.
Non-destructive headspace analysis is the only technology able to detect transient leaks in statistically relevant sample sets – and with unprecedented sensitivity. Unlike traditional methods, headspace CCI testing provides consistent, repeatable results independent of operator variability. When paired with residual seal force (RSF) data, this method becomes a science-based approach to assess and optimize the vial sealing process for closure integrity during cold storage.
A CCI testing strategy using headspace analysis proves particularly valuable for high-value products. Collecting statistically meaningful data on packaging and process parameters for advanced biologics, gene therapies, and other specialty pharmaceuticals enables a thorough closure integrity assessment—without compromising product availability for clinical or commercial use. The following case study further demonstrates that value.
Case Study - Gene Therapy Product CCIT at -80°C
A pharmaceutical manufacturer developing a gene therapy product needed to validate their packaging system for deep cold storage. They understood that traditional testing methods provided insufficient insight into CCI for the required storage conditions.
Using headspace CO₂ analysis, in combination with RSF measurements, they tested different vial-stopper combinations at a range of crimping settings to understand which configuration performed best at -80°C. Working systematically, the development team varied crimping parameters to generate statistically valid data to correlate seal quality with CCI during deep cold storage.
Two packaging designs were evaluated:
Vial-Stopper Combination X: demonstrated consistent integrity failures when the sealing pressure fell below a certain level, with looser seals leading to CO₂ ingress and a loss in CCI. The data clearly shows that this packaging system needs very precisely controlled, tight crimping specifications to maintain closure integrity.
Vial-Stopper Combination Y: maintained full closure integrity across a wide range of sealing pressures, offering greater flexibility and a wider process design space. Unlike the first combination, this packaging system maintained excellent container closure integrity across the full range of sealing pressures that were tested.
By combining residual seal force (RSF) measurements with headspace CCI test data, the team identified the most robust packaging setup—ensuring CCI under extreme conditions.
The systematic approach didn’t just verify closure integrity—it delivered data-driven insight that shaped manufacturing decisions, enabling science-based selection of packaging components and sealing parameters. This kind of data-driven comparison provides valuable insight for packaging component selection and process validation—especially for temperature sensitive therapies.
Cold Chain CCIT and EU GMP Annex 1 / FDA Guidance
Regulatory agencies worldwide have intensified their focus on cold chain integrity as advanced therapies become more prevalent, with the FDA, EMA, and other authorities recognizing that traditional CCI testing approaches may be inadequate for products requiring extreme temperature storage conditions.
Authorities now emphasize the use of deterministic methods for CCIT, as outlined in USP <1207>. Current regulatory guidance emphasizes the importance of deterministic testing methods over probabilistic approaches for container closure integrity assessment. As demonstrated in the above case study, headspace analysis is not only compliant with these requirements, but it also aligns perfectly with regulatory preferences for repeatability, sensitivity, and real-world relevance.
In addition, the regulatory emphasis on a lifecycle approach to CCI testing requires manufacturers to demonstrate packaging performance under actual storage conditions rather than relying on accelerated or ambient temperature studies. Headspace analysis provides the quantitative evidence needed to satisfy regulatory expectations while supporting risk-based quality systems.
In particular, headspace CCIT plays a vital role in detecting temporary leaks that traditional, probabilistic methods miss—a capability that is specifically relevant for CCI testing of products requiring cold storage.
Don’t wait for a failure to uncover your cold chain vulnerabilities.
CCIT Method Development for Cold Chain Products
Navigating the complexities of ultra-low and cryogenic storage requires more than just standard container closure integrity testing; it demands a robust, product-specific CCIT method tailored to the transient leaks that are unique to deep cold environments. A standard ambient-temperature test can simply not be applied to a cold chain product without adaptation.
Developing a reliable, science-based CCIT method for cold chain packaging involves taking into account the conditions your product will get exposed to. This ensures that transient leaks—which only occur when the vial is deeply frozen and reseals upon warming—can be accurately detected. By establishing an optimized, deterministic approach early in the product lifecycle, you ensure the method achieves the necessary limit of detection (LOD) and sensitivity without compromising high-value biologics or cell and gene therapies.
Once a robust method is developed to the specific vulnerabilities of your cold chain packaging, the next crucial step is demonstrating its regulatory compliance and reproducibility through formal validation. To learn more about our rigorous step-by-step approach to establishing and verifying these protocols under ICH Q2(R2) guidelines, explore our comprehensive CCIT Method Validation & Development approach.
Request Cold Chain Testing Support
Whether you’re developing a new product or you’re optimizing existing primary packaging, and need to validate packaging for -80°C storage, LIGHTHOUSE offers the expertise and technology to ensure your CCIT strategy is airtight—literally.
Our team of specialists understands the unique challenges of ultra cold storage and distribution and can help you implement robust testing strategies that ensure closure integrity throughout the cold chain.
Our support includes:
- Headspace method development and validation
- Comparative packaging studies for optimal component selection
- Process optimization through RSF-CCI correlation analysis
- Routine batch testing for ultra cold storage products
From feasibility studies to full implementation, we help you build confidence in your cold chain closure integrity. Our headspace analysis technology delivers the sensitivity, reliability, and regulatory compliance necessary for today’s demanding pharmaceutical applications.
Contact our experts to discuss your specific CCI testing challenges and discover how we can help protect your products and patients.
Not yet ready to chat, but you would like to learn more?
Get the full case study – complete with test methods, data, and actionable takeaways. Learn how to:
- Apply RSF and headspace testing to validate your sealing process
- Select the right vial-stopper combination for -80°C storage
- Design a compliant, data-driven approach to CCI for cold chain conditions